Navigation Links
Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Date:12/10/2008

SAN DIEGO, Dec. 10 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets, today announced the commencement of patient dosing for a Phase 1 clinical trial for a bisphosphonate administered with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20) as a subcutaneous (SC) injection. This study will explore the safety, tolerability and pharmacokinetics of SC administration of a bisphosphonate plus rHuPH20. Currently, injectable bisphosphonates must be administered intravenously (IV).

"We are pleased that the first clinical trial is underway for our bisphosphonate program, our third proprietary product development initiative to enter clinical studies," stated Jonathan Lim, M.D., President and CEO of Halozyme Therapeutics. "The bisphosphonate program joins insulin, for diabetes, and Chemophase, for superficial bladder cancer, our other two proprietary programs in clinical development. The goal of Halozyme's bisphosphonate program is to provide an alternative dosage formulation that may offer greater convenience, compliance and tolerability to patients for the treatment of osteoporosis."

This Phase 1 dose ranging clinical trial will assess the safety, tolerability and pharmacokinetics of a bisphosphonate with and without co-administration of rHuPH20 across a range of bisphosphonate concentrations and volumes and various rHuPH20 doses. The study will also compare SC administration of a bisphosphonate plus rHuPH20 to IV bisphosphonate alone.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for t
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
2. Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
3. Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial
4. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
5. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
6. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
7. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
8. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
9. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
10. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 2015  Thoratec Corporation (NASDAQ: THOR ), a ... support and restore failing hearts, said today it will ... Healthcare Conference on Thursday, May 14. ... will provide an update on the company, beginning at ... Time). The presentation will be available through ...
(Date:4/30/2015)... 30, 2015  DURECT Corporation (Nasdaq: DRRX ) ... 2015.  Total revenues were $4.8 million and net loss ... 31, 2015 as compared to total revenues of $6.3 ... three months ended March 31, 2014.At March 31, 2015, ... to cash and investments of $34.9 million at December ...
(Date:4/30/2015)... Company plc (NYSE: PRGO ; TASE) today announced that Perrigo ... at the 2015 Deutsche Bank 40 th Annual Healthcare Conference ... Hotel in Boston , MA.  ... Joseph C. Papa will present at the Bank of America ... 12, 2015 at the Encore at Wynn Las Vegas Hotel in ...
Breaking Medicine Technology:Thoratec Presentation At Bank Of America Merrill Lynch Healthcare Conference To Be Webcast 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9Perrigo Company To Present At Upcoming Healthcare Conferences 2Perrigo Company To Present At Upcoming Healthcare Conferences 3
(Date:5/2/2015)... 02, 2015 On Tuesday April 7th, ... (ELCH) gathered to celebrate improvements in patient care. In ... Partners (RVHP), had zero acquired ventilator associated infections, zero ... infections. ELCH was also recently named a Top Performer ... at ELCH credited the teamwork of staff from all ...
(Date:5/2/2015)... 02, 2015 With the success that Veatch ... proud to welcome Neida Miranda and Alex Shields to the ... has over 41 years of combined experience working with dentists ... the dental field for 8 years. She was certified ... Texas. Customer service, positive attitude and showing the importance of ...
(Date:5/1/2015)... May 01, 2015 Jusuru International has ... the successful repositioning of its flagship nutritional supplement, Liquid ... with a new name, new logo, new packaging, new ... Awards are designed to identify and promote programs that ... , “DSA congratulates Jusuru International for their outstanding ...
(Date:5/1/2015)... 2015 It’s raining bills on Capitol Hill ... to expand federal support for telemedicine. , “Such ... been working with Congress,” said Jonathan Linkous, CEO of the ... nation is poised to embrace the use of telecommunications in ... in fulfilling ATA’s mission to improve quality, access, equity and ...
(Date:5/1/2015)... 2015 The Quail Creek Relay for Life ... Since 2001, the Quail Creek Relay team has raised almost ... throughout the year, including their biggest event, January’s Dinner and ... , Quail Creek Relay for Life team was established ... Kerwin, fitness director, states, “I was hooked when I learned ...
Breaking Medicine News(10 mins):Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:Veatch Dental Consulting Services Welcomes New Team Members 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:Quail Creek Country Club’s Relay for Life Team Raised Over $89,000 for American Cancer Society 2
... Controversial food byproduct even showed protection for women, study ... a food byproduct that some research has linked to ... in men and may even offer slight protection for ... included more than 120,000 men and women, Dutch researchers ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ... invited to listen to the conference call that will be ... at 4:30 pm Eastern Time (1:30 pm Pacific Time).A live ... DURECT,s homepage at http://www.durect.com ...
... , , CHICAGO , April 28 ... Association,s (AUA) Annual Conference show that RAPAFLO (TM) ... both irritative and obstructive urinary symptoms associated with BPH, ... days of starting treatment. RAPAFLO (TM) ...
... statin medications have been found to have numerous other ... developing advanced prostate cancer, as well as lowering his ... by researchers at Henry Ford Hospital finds that statins ... cancer, potentially altering the results of a patient,s PSA ...
... Honored by Massachusetts LegislatureBEDFORD, Mass., April 28 ... visual impairment or his diabetes keep him from sailing ... members from the Carroll Center for the Blind in ... Division at the 2009 Blind Sailing World Championship Regatta ...
... Rules and Silences Opposition DebateCHESAPEAKE, Va., April 28 ... they will lack the necessary 60 votes required ... House and Senate Democrats last night struck a ... meaningful debate and drops the number of needed ...
Cached Medicine News:Health News:Acrylamide Doesn't Raise Lung Cancer Risk 2Health News:Acrylamide Doesn't Raise Lung Cancer Risk 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 2Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 3Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 4Health News:Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients 5Health News:Statins alter prostate cancer patients' PSA levels 2Health News:Insulet Applauds Employee for Bronze Medal Performance in World Blind Sailing Championships 2Health News:Fast-Track of Socialized Healthcare Imminent 2
Rounded tip for even incisions reducing post-op astigmatism...
... with 12 bevel tip; silicone ... bevel is opposite curve, Designed ... fluid, Sleeve acts as stop ... minimize chance of trauma to ...
Designed to meet the needs of pediatric surgery and paracentesis...
Designed for stab incisions...
Medicine Products: